menu search

CLSN / Celsion and Medidata to Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial

Celsion and Medidata to Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial
Phase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients to be presented at 2022 AACR A nnual M eeti ng being held April 8-13 in New Orleans, LA Read More
Posted: Apr 6 2022, 08:30
Author Name: GlobeNewsWire
Views: 110259

CLSN News  

Celsion Corporation (CLSN) CEO Michael Tardugno on Q1 2022 Results - Earnings Call Transcript

By Seeking Alpha
May 16, 2022

Celsion Corporation (CLSN) CEO Michael Tardugno on Q1 2022 Results - Earnings Call Transcript

Celsion Corporation (NASDAQ:CLSN ) Q1 2022 Earnings Conference Call May 16, 2022 11:00 AM ET Company Participants Monique Kosse - Investor Relations M more_horizontal

Why Celsion Shares Are Pulling Back Today

By Benzinga
April 6, 2022

Why Celsion Shares Are Pulling Back Today

Celsion Corp (NASDAQ: CLSN) shares are trading lower Wednesday after the company announced a $7 million registered direct offering priced at-the-mark more_horizontal

Celsion and Medidata to Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial

By GlobeNewsWire
April 6, 2022

Celsion and Medidata to Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial

Phase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients to be presented at 2022 AACR A nnual M eeti ng being held Apri more_horizontal

Why Celsion Stock Is Surging Today

By Benzinga
April 5, 2022

Why Celsion Stock Is Surging Today

Celsion Corp (NASDAQ: CLSN) shares are trading higher Tuesday as traders circulate a Zacks Small-Cap Research note with a $37 valuation target on the more_horizontal

Celsion Corporation's (CLSN) CEO Michael Tardugno on Q4 2021 Results - Earnings Call Transcript

By Seeking Alpha
March 31, 2022

Celsion Corporation's (CLSN) CEO Michael Tardugno on Q4 2021 Results - Earnings Call Transcript

Celsion Corporation's (CLSN) CEO Michael Tardugno on Q4 2021 Results - Earnings Call Transcript more_horizontal

Celsion Corporation to Hold Year-End 2021 Financial Results and Business Update Conference Call on Thursday, March 31, 2022

By GlobeNewsWire
March 24, 2022

Celsion Corporation to Hold Year-End 2021 Financial Results and Business Update Conference Call on Thursday, March 31, 2022

LAWRENCEVILLE, N.J., March 24, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation  (NASDAQ: CLSN), a clinical-stage development company focused on DNA-base more_horizontal

Celsion (CLSN) Stock: 1-For-15 Reverse Split Goes Into Effect

By Pulse2
March 1, 2022

Celsion (CLSN) Stock: 1-For-15 Reverse Split Goes Into Effect

A 1-for-15 reverse split of Celsion Corporation (NASDAQ: CLSN) stock has gone into effect. These are the details. more_horizontal

Celsion (CLSN) Stock: 1-For-15 Reverse Split Goes Into Effect

By Pulse2
March 1, 2022

Celsion (CLSN) Stock: 1-For-15 Reverse Split Goes Into Effect

A 1-for-15 reverse split of Celsion Corporation (NASDAQ: CLSN) stock has gone into effect. These are the details. more_horizontal


Search within

Pages Search Results: